Skip to main content

Advertisement

SpringerLink
Log in

Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy in the treatment of patients with glaucoma.

Methods

To measure the main treatment effects of a fixed combination of brimonidine 0.2%-timolol 0.5%, we conducted three small studies: (1) a comparison of diurnal intraocular pressure (IOP) at baseline and at 6 months after brimonidine/timolol fixed-combination therapy (n = 81); (2) an assessment of the effects of one drop of the brimonidine/timolol fixed combination on diurnal IOP (n = 25); and (3) the effects of brimonidine/timolol fixed-combination therapy on the anterior ocular segment over time (n = 64).

Results

(1) After 6 months of treatment with the brimonidine/timolol fixed combination, the mean diurnal IOP in primary open-angle glaucoma (POAG) decreased from 21.4 ± 2.0 to 14.5 ± 3.1 mmHg (32.2%, P < 0.001), and the mean diurnal IOP in normal-tension glaucoma (NTG) decreased from 13.5 ± 2.8 to 10.9 ± 2.0 mmHg (19.3%, P < 0.001). (2) After instillation with one drop of the brimonidine/timolol fixed combination, the IOP in the instilled eye was lowest at 9:00 p.m. and had decreased by 1.7 mmHg compared with the baseline IOP in the instilled eye. The difference in IOP between the instilled eye and untreated fellow eye was largest at 3:00 p.m., measuring 1.7 mmHg (P = 0.011). (3) Brimonidine/timolol fixed-combination therapy caused significant miosis over time (P = 0.003).

Conclusions

The results of this study suggest that brimonidine/timolol fixed-combination therapy has beneficial IOP-lowering effects and significant effects on pupil size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M.s Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–1279.

    PubMed  Google Scholar 

  2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–713.

    PubMed  Google Scholar 

  3. Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol 2003; 121:777–783.

    Article  PubMed  Google Scholar 

  4. Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960;64: 494–501.

    CAS  PubMed  Google Scholar 

  5. Tajunisah I, Reddy SC, Fathilah J. Diurnal variation of intraocular pressure in suspected glaucoma patients and their outcome. Graefes Arch Clin Exp Ophthalmol 2007; 245:1851–1857.

    Article  CAS  PubMed  Google Scholar 

  6. Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581–590.

    CAS  PubMed  Google Scholar 

  7. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230–1238.

    Article  CAS  PubMed  Google Scholar 

  8. Iwase A, Suzuki Y, Araie M, et al.; Tajimi Study Group, Japan Glaucoma Society. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 2004;111: 1641–1648.

    Google Scholar 

  9. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130:429–440.

    Article  Google Scholar 

  10. Koseki N, Araie M, Shirato S, Yamamoto S. Effect of trabeculectomy on visual field performance in central 30 degrees field in progressive normal-tension glaucoma. Ophthalmology 1997;104: 197–201.

    CAS  PubMed  Google Scholar 

  11. Abedin S, Simmons RJ, Grant WM. Progressive low-tension glaucoma: treatment to stop glaucomatous cupping and field loss when these progress despite normal intraocular pressure. Ophthalmology 1982;89:1–6.

    CAS  PubMed  Google Scholar 

  12. Sit AJ. Continuous monitoring of intraocular pressure: rationale and progress toward a clinical device. J Glaucoma 2009;18: 272–279.

    Article  PubMed  Google Scholar 

  13. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R; Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337–348.

    Article  CAS  PubMed  Google Scholar 

  14. Ishibashi S, Hirose N, Tawara A, Kubota T. Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma. J Glaucoma 2006;15: 354–357.

    Article  PubMed  Google Scholar 

  15. Potter DE, Crosson CE, Heath AR, Ogidigben MJ. Review: alpha 2 and DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential. J Ocul Pharmacol 1990;6:251–257.

    Article  CAS  PubMed  Google Scholar 

  16. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514–1517.

    CAS  PubMed  Google Scholar 

  17. Wayman L, Larsson LI, Maus T, Alm A, Brubaker R. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:1368–1371.

    CAS  PubMed  Google Scholar 

  18. Bhorade AM. The monocular trial controversy: a critical review. Curr Opin Ophthalmol 2009;20:104–109.

    Article  PubMed  Google Scholar 

  19. Drance SM. The uniocular therapeutic trial in management of elevated IOP. Surv Ophthalmol 1980; 25:203–205.

    Article  CAS  PubMed  Google Scholar 

  20. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95:601–604.

    CAS  PubMed  Google Scholar 

  21. Piltz J, Gross R, Shin DH, et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2000;130: 441–453.

    Article  CAS  PubMed  Google Scholar 

  22. Kim MS, Kim JM, Park KH, Choi CY. Asymmetry of diurnal intraocular pressure fluctuation between right and left eyes. Acta Ophthalmol [Epub ahead of print Oct 23 2009].

  23. McDonald JE II, El-Moatassem Kotb AM, Decker BB. Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions. J Cataract Refract Surg 2001;27:560–564.

    Article  PubMed  Google Scholar 

  24. Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in cats. Am J Vet Res 1991;52:436–440.

    CAS  PubMed  Google Scholar 

  25. Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in dogs. Am J Vet Res 1991;52:432–435.

    CAS  PubMed  Google Scholar 

  26. Boger WP III, Puliafito CA, Steinert RF, Langston DP. Long-term experience with timolol ophthalmic solution in patients with openangle glaucoma. Ophthalmology 1978;85:259–267.

    PubMed  Google Scholar 

  27. Thordsen JE, Bower KS, Warren BB, Stutzman R. Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes. J Cataract Refract Surg 2004;30:1702–1706.

    Article  PubMed  Google Scholar 

  28. Brown SM, Khanani AM, McCartney DL. The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter. Am J Ophthalmol 2004;138:149–151.

    Article  CAS  PubMed  Google Scholar 

  29. Gordon MO, Kass MA, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999; 117:573–583.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Korea

    Sung Woo Cho, Joon Mo Kim & Chul Young Choi

  2. Department of Ophthalmology, Seoul National University School of Medicine, Seoul National University Hospital, Seoul, Korea

    Ki Ho Park

  3. Department of Ophthalmology, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, 108 Pyung-Dong, Jongro-Ku, Seoul, 110-746, Korea

    Joon Mo Kim

Authors
  1. Sung Woo Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joon Mo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ki Ho Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chul Young Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joon Mo Kim.

About this article

Cite this article

Cho, S.W., Kim, J.M., Park, K.H. et al. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma. Jpn J Ophthalmol 54, 407–413 (2010). https://doi.org/10.1007/s10384-010-0855-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-010-0855-4

Keywords

Search

Navigation